Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation Sixty-five empirical papers were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback